148 related articles for article (PubMed ID: 10629005)
1. Carbapenems: the pinnacle of the beta-lactam antibiotics or room for improvement?
Edwards JR; Betts MJ
J Antimicrob Chemother; 2000 Jan; 45(1):1-4. PubMed ID: 10629005
[No Abstract] [Full Text] [Related]
2. Doripenem.
Anderson DL
Drugs Today (Barc); 2006 Jun; 42(6):399-404. PubMed ID: 16845443
[TBL] [Abstract][Full Text] [Related]
3. Increased susceptibility to antibiotics in gram-negative and gram-positive pathogens, including Pseudomonas aeruginosa, at lower temperature: is antibiotic resistance reversal possible?
Moore JE; Moore PJA; Downey D; Millar BC; Coulter WA; Goldsmith CE
Br J Biomed Sci; 2013; 70(4):173-4. PubMed ID: 24400429
[No Abstract] [Full Text] [Related]
4. Antimicrobial resistance among and therapeutic options against gram-negative pathogens.
Rahal JJ
Clin Infect Dis; 2009 Aug; 49 Suppl 1():S4-S10. PubMed ID: 19619021
[TBL] [Abstract][Full Text] [Related]
5. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa.
Thomson KS; Moland ES
J Antimicrob Chemother; 2004 Aug; 54(2):557-62. PubMed ID: 15201229
[TBL] [Abstract][Full Text] [Related]
6. [Carbapenem antibiotics].
Watanabe A
Nihon Rinsho; 2003 Feb; 61 Suppl 2():737-43. PubMed ID: 12722309
[No Abstract] [Full Text] [Related]
7. Surveillance and management of multidrug-resistant microorganisms.
Orsi GB; Falcone M; Venditti M
Expert Rev Anti Infect Ther; 2011 Aug; 9(8):653-79. PubMed ID: 21819331
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antibacterial activity of 1beta-methyl-2-[5-(N-substituted-2-hydroxy iminoethyl)pyrrolidin-3-ylthio]carbapenem derivatives.
Oh CH; Lee SC; Cho JH
Eur J Med Chem; 2003; 38(7-8):751-8. PubMed ID: 12932906
[TBL] [Abstract][Full Text] [Related]
9. [Available carbapenems: Properties and differences].
Martínez MJ; García MI; Sánchez EG; Sánchez JE
Enferm Infecc Microbiol Clin; 2010 Sep; 28 Suppl 2():53-64. PubMed ID: 21130931
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial properties of BO-2727, a new carbapenem antibiotic.
Kato Y; Otsuki M; Nishino T
J Antimicrob Chemother; 1997 Aug; 40(2):195-203. PubMed ID: 9301984
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial Susceptibility among European Gram-Negative and Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation and Surveillance Trial (2004-2014).
Rodloff AC; Dowzicky MJ
Chemotherapy; 2017; 62(1):1-11. PubMed ID: 27216271
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.
Mohanty S; Maurya V; Gaind R; Deb M
J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048
[TBL] [Abstract][Full Text] [Related]
13. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
[No Abstract] [Full Text] [Related]
14. Synthesis and biological activities of an alpha-methyl and a beta-methyl carbapenem and the corresponding unsubstituted compound.
Pfaendler HR; Weishaupt R; Meffert H
Bioorg Med Chem Lett; 2000 Jun; 10(12):1389-91. PubMed ID: 10890171
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
Koga T; Abe T; Inoue H; Takenouchi T; Kitayama A; Yoshida T; Masuda N; Sugihara C; Kakuta M; Nakagawa M; Shibayama T; Matsushita Y; Hirota T; Ohya S; Utsui Y; Fukuoka T; Kuwahara S
Antimicrob Agents Chemother; 2005 Aug; 49(8):3239-50. PubMed ID: 16048932
[TBL] [Abstract][Full Text] [Related]
16. The challenge of multidrug resistance: the treatment of gram-negative rod infections.
Levin AS; Oliveira MS
Shock; 2008 Oct; 30 Suppl 1():30-3. PubMed ID: 18704012
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens.
Watanabe A; Takahashi H; Kikuchi T; Kobayashi T; Gomi K; Fujimura S; Tokue Y; Nukiwa T
Chemotherapy; 2000; 46(3):184-7. PubMed ID: 10765033
[TBL] [Abstract][Full Text] [Related]
18. NDM-1 (New Delhi metallo beta lactamase-1) producing Gram-negative bacilli: emergence & clinical implications.
Fomda BA; Khan A; Zahoor D
Indian J Med Res; 2014 Nov; 140(5):672-8. PubMed ID: 25579151
[TBL] [Abstract][Full Text] [Related]
19. Treatment of multidrug-resistant Gram-negative infections in children.
Hsu AJ; Tamma PD
Clin Infect Dis; 2014 May; 58(10):1439-48. PubMed ID: 24501388
[TBL] [Abstract][Full Text] [Related]
20. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
